Patent intelligence · US
US 6268350
Polynucleotides for inhibiting metastasis and tumor cell growth
Polynucleotides for inhibiting metastasis and tumor cell growth
Patent details — US 6268350
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 31, 2001
- Expiration
- Jul 26, 2021
- Applicant
- BioCrystal, Ltd.
- Claims
- 10
- CPC classes
- A61K, A61K38/177, A61K48/00, A61P
Quick answer
US 6268350 (Polynucleotides for inhibiting metastasis and tumor cell growth) is held by BioCrystal, Ltd.. Status: expired. Granted Jul 31, 2001. Expires Jul 26, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioCrystal, Ltd.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/177, A61K48/00, A61P, A61P35/04
More from BioCrystal, Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12162838
Human plasma kallikrein inhibitors
granted -
US 12121503
Antiviral treatments
granted -
US 12116346
Human plasma kallikrein inhibitors
granted -
US 12054492
Imidazole-containing inhibitors of ALK2 kinase
granted -
US 12043610
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted -
US 11975003
Methods and compositions for treatment of Zika virus infection
granted -
US 11866418
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted
Frequently asked questions
What is US patent 6268350?
US 6268350 (Polynucleotides for inhibiting metastasis and tumor cell growth) is held by BioCrystal, Ltd.. Status: expired. Granted Jul 31, 2001. Expires Jul 26, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6268350?
BioCrystal, Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 6268350 expire?
Our index shows an expiration date of Jul 26, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.